The Skin Side Effects of Topical Glucantime in Patients with Cutaneous Leishmaniasis

Document Type : Original Article (s)

Authors

1 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Dermatologist, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan AND Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 General Practitioner, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Cutaneous leishmaniasis (CL) is endemic in many parts of Iran and is discussed as a health issue. Although it has spontaneously remitting course, but the treatment is often recommended to shorten the duration of illness and limit the size of the scar. First-line therapy is topical or systemic glucantime; but because of its serious complications, it is attempted to find better drugs with fewer side effects. This study aimed to assess the skin reactions in patients with cutaneous leishmaniasis treated with topical glucantime.Methods: This prospective cohort study was performed on all patients with cutaneous leishmaniasis treated with topical glucantime and referred to the Skin and Leishmaniasis Research Center, Isfahan, in 2010-2011. Skin side effects caused by this type of the treatment were analyzed.Findings: 130 patients with cutaneous leishmaniasis treated with topical glucantime were studied. The mean age of the patients was 16.38 ± 23.97 years. In 38.5 percent of patients, skin side effects were observed that were mainly maculopapuler rashs with pruritic (12.3 percent). The mean duration of treatment initiation until the appearance of skin side effects was 12.66 ± 20.98 days. There was no significant relationship between the clinical type and the site of the lesions and the appearance of skin side effects (P > 0.05).Conclusion: Skin side effects were mainly maculopapuler rashes with pruritic in patients with cutaneous leishmaniasis treated with topical glucantime. According to skin side effects induced by topical glucantime, importance and necessity of the injection method and the use of adjuvant therapy is emphasized according to indications of topical treatment of patients with cutaneous leishmaniasis.

Keywords

References

  1. Vega Lopez F, Hay RJ. Parasitic worms and protozoa. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's text book of dermatology. 8th ed. Hoboken, NJ: Blackwell Science; 2010. p. 33-44.
  2. Al-Jaser MH. Treatment trends of cutaneous leishmaniasis in Saudi Arabia. Saudi Med J 2005; 26(8): 1220-4.
  3. Gonzalez U. Fluconazole for cutaneous leishmaniasis: looking for a better treatment. Arch Dermatol 2002; 138(12): 1604-6.
  4. Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 2002; 41(7): 441-3.
  5. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003; 16(5): 397-401.
  6. Nilforoushzadeh MA, Sadeghian G. Cutaneous leishmaniasis. Isfahan, Iran: Oroog Publications; 2002. p. 114. [In Persian].
  7. Hardman JG, Limbird LE, Gilman AG. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001. p. 111-3.
  8. Sharquie KE, Al-Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119(1): 53-7.
  9. Dowlati Y. Treatment of cutaneous leishmaniasis (Old World). Clin Dermatol 1996; 14(5): 513-7.
  10. Stern RS, Shear NH. Cutaneous reactions to drugs and biological modifiers. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors. Cutaneous medicine and surgery. Philadelphia, PA: Saunders; 1996.
  11. Laguna F, Lopez-Velez R, Soriano V, Montilla P, Alvar J, Gonzalez-Lahoz JM. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 1994; 28(3): 255-9.
  12. Canizares O. The Leishmaniasis. In: Canizares O, Harman R, editors. Clinical tropical dermatology.Oxford, UK: Blackwell Scientific; 1975. p. 185-204.
  13. Herwaldt BL. Leishmaniasis. Lancet 1999; 354(9185): 1191-9.
  14. Weigle K, Saravia NG. Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis. Clin Dermatol 1996; 14(5): 433-50.
  15. World Health Organization. The leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1984; 701: 1-140.
  16. Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar MP, Moghiman T, Ashraf H, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res 2011; 2011: 656523.
  17. Marinkelle CJ. The control of leishmaniases. Bull World Health Organ 1980; 58(6): 807-18.
  18. Neva F, Sacks D. Leishmaniasis in tropical and geographical medicine. 2nd ed. New York, NY: McGraw-Hill; 1990. p. 296-307.
  19. Beheshti M, Ghotbi S, Amirizade S. Therapeutic and adverse effects of Glucantime used for treatment of cutaneous leishmaniasis. Shiraz E-Med J 2007; 8(4 SP 155-161).
  20. Masmoudi A, Maalej N, Boudaya S, Turki H, Zahaf A. Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis. Med Mal Infect 2006; 36(4): 226-8. [In French].
  21. Sadeghian G, Nilfroushzadeh MA, Siadat AH. A comparison between intralesional hypertonic sodium chloride solution and meglomine antimoniate in the treatment of cutaneous leishmaniasis. Egyptian Dermatol Online J 2006; 2(1): 8.
  22. Romero GA, Flores MR, Noronha EF, Macedo VO. High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls. Mem Inst Oswaldo Cruz 2003; 98(1): 145-9.
Journal of Isfahan Medical School
Volume 33, Issue 338 - Serial Number 338
May and June 2015
Pages 884-890

Files

History

  • Receive Date: 15 December 2014
  • Revise Date: 01 June 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics